Assessing adequate treatment response in patients with rheumatoid arthritis

Clinical Therapeutics

Volumn 31, Issue 6, 2009, Pages 1219-1231

  Bergman, Martin Jan ^a,b  

^a Taylor Hospital   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

outcome measures; rheumatoid arthritis; treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINOLONE; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; JOINT RADIOGRAPHY; MONOTHERAPY; OUTCOME ASSESSMENT; RECOMMENDED DRUG DOSE; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

EID: 68649121665     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.06.005     Document Type: Note

References (93)

1. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Handout on health: Rheumatoid arthritis. http://www.niams.nih.gov/Health_Info/Rheumatic_Disease/default.asp Accessed September 9, 2008
2. Helmick C.G., Felson D.T., Lawrence R.C., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58 (2008) 15-25
3. Dunlop D.D., Manheim L.M., Yelin E.H., et al. The costs of arthritis. Arthritis Rheum. 49 (2003) 101-113
4. Burton W., Morrison A., Maclean R., and Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond). 56 (2006) 18-27
5. Kosinski M., Kujawski S.C., Martin R., et al. Health-related quality of life in early rheumatoid arthritis: Impact of disease and treatment response. Am J Manag Care 8 (2002) 231-240
6. Uhlig T., Loge J.H., Kristiansen I.S., and Kvien T.K. Quantification ofreduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol. 34 (2007) 1241-1247
7. Kavanaugh A., Han C., and Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol. 31 (2004) 849-855
8. Puolakka K., Kautiainen H., Pekurin-en M., et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: Experience from the FIN-RACo trial. Ann Rheum Dis. 65 (2006) 899-904
9. Sokka T., and Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol. 30 (2003) 1138-1146
10. Fischer D., Stewart A.L., Bloch D.A., et al. Capturing the patient's view of change as a clinical outcome measure. JAMA 282 (1999) 1157-1162
11. Marshall N.J., Wilson G., Lapworth K., and Kay L.J. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: A qualitative study. Rheumatology (Oxford) 43 (2004) 1034-1038
12. Emery P. Treatment of rheumatoid arthritis. BMJ 332 (2006) 152-155
13. Weaver A.L. The impact of new bio-logicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 43 Suppl 3 (2004) iii17-iii23
14. Enbrel (etanercept) [package insert] (2006), Immunex Corporation, Thousand Oaks, Calif
15. Humira (adalimumab) [package insert] (2008), Abbott Laboratories, North Chicago, Ill
16. Kineret (anakinra) [package insert] (2006), Amgen, Thousand Oaks, Calif
17. Orencia (abatacept) [package insert] (2008), Bristol-Myers Squibb, Princeton, NJ
18. Rituxan (rituximab) [package insert] (2008), Biogen Idec Inc., South San Francisco, Calif and Genentech USA, Inc
19. Remicade (infliximab) [package insert] (2007), Centocor, Inc, Malvern, Pa
20. Sesin C.A., and Bingham III C.O. Remission in rheumatoid arthritis: Wishful thinking or clinical reality?. Semin Arthritis Rheum. 35 (2005) 185-196
21. Furst D., Genovese M., Kremer J., et al. Defining treatment failure and success in rheumatoid arthritis and practical applications of new biologics. http://www.medscape.com/viewprogram/6721 Accessed September 9, 2008
22. Wolfe F., Michaud K., and Dewitt E.M. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: Methodological and interpretive issues. Ann Rheum Dis. 63 Suppl 2 (2004) ii13-ii17
23. Felson D.T., Anderson J.J., Boers M., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38 (1995) 727-735
24. Dept of Rheumatology, University Medical Centre, Nijmegen, the Netherlands. Disease Activity Score in rheumatoid arthritis. http://www.das-score.nl/www.das-score.nl/ Accessed September 5, 2008.
25. Weinblatt M.E., Kremer J.M., Bankhurst A.D., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 340 (1999) 253-259
26. Maini R., St Clair E.W., Breedveld F., et al., the ATTRACT Study Group. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 354 (1999) 1932-1939
27. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial [published correction appears in Arthritis Rheum. 2003;48:855]. Arthritis Rheum. 48 (2003) 35-45
28. Chung C.P., Thompson J.L., Koch G.G., et al. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. Ann Rheum Dis. 65 (2006) 1602-1607
29. Shaver T., Shahouri S., Anderson J., et al. The outcome of aggressive biologic therapy in clinical practice: Measurement by DAS remission and minimal disease activity (MDA). Presented at: American College of Rheumatology 71st Annual Meeting. Boston, Mass, November 10-11 (2007) Abstract 323
30. Shaver T.S., Anderson J.D., Weidensaul D.N., et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol. 35 (2008) 1015-1022
31. Pincus T., Swearingen C.J., Bergman M., and Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: Proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 35 (2008) 2136-2147
32. Smolen J.S., Breedveld F.C., Schiff M.H., et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatologr(Oxford) 42 (2003) 244-257
33. Aletaha D., Nell V.P., Stamm T., et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res Ther. 7 (2005) R796-R806
34. Aletaha D., and Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 23 Suppl 39 (2005) S100-S108
35. Boers M., and the COBRA Study Group. Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: The paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy. Arthritis Rheum. 44 (2001) 2703-2704
36. Smolen J.S., Han C., Bala M., et al., the ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 52 (2005) 1020-1030
37. Molenaar E.T., Voskuyl A.E., Dinant H.J., et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 50 (2004) 36-42
38. Sokka T., and Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum. 48 (2003) 313-318
39. Zink A., Strangfeld A., Schneider M., et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 54 (2006) 3399-3407
40. Kingsley G.H., Khoshaba B., Smith C.M., et al. Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria. Rheumatology (Oxford) 44 (2005) 629-632
41. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al., the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 343 (2000) 1594-1602
42. Klareskog L., van der Heijde D., de Jager J.P., et al., the Trial of Etaner-cept and Methotrexate with Radiographic Patient Outcomes (TEMPO) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 363 (2004) 675-681
43. Moreland L.W., Schiff M.H., Baumgartner S.W., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 130 (1999) 478-486
44. van de Putte L.B., Atkins C., Malaise M., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 63 (2004) 508-516
45. Duclos M., Gossec L., Ruyssen-Witrand A., et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol. 33 (2006) 2433-2438
46. Strand V., Cohen S., Crawford B., et al., the Leflunomide Investigators Group. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford). 43 (2004) 640-647
47. US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: Use in medical product development to support labeling claims. http://www.fda.gov/cder/guidance/5460dft.htm Accessed September 5, 2008
48. Lubeck D.P. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmaco Economics. 22 Suppl 1 (2004) 27-38
49. Guyatt G.H., Osoba D., Wu A.W., et al., the Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 77 (2002) 371-383
50. Westhovens R., Cole J.C., Li T., et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 45 (2006) 1238-1246
51. Russell A.S., Wallenstein G.V., Li T., et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis. 66 (2007) 189-194
52. Boers M., Verhoeven A.C., Markusse H.M., et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [published correction appears in Lancet. 1998;35:220]. Lancet 350 (1997) 309-318
53. Genovese M.C., Bathon J.M., Martin R.W., et al. Etanercept versus metho- trexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum. 46 (2002) 1443-1450
54. Korpela M., Laasonen L., Hannonen P., et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: Five-year experience from the FIN-RACo study. Arthritis Rheum. 50 (2004) 2072-2081
55. Breedveld F.C., Emery P., Keystone E., et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis. 63 (2004) 149-155
56. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 52 (2005) 3381-3390
57. Breedveld F.C., Weisman M.H., Ka-vanaugh A.F., et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus metho-trexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54 (2006) 26-37
58. Verstappen S.M., Jacobs J.W., van der Veen M.J., et al., the Utrecht Rheumatoid Arthritis Cohort study group. Intensive treatment with methotrexate in early rheumatoid arthritis: Aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). AnnRheumDis. 66 (2007) 1443-1449
59. Quinn M.A., and Emery P. Window of opportunity in early rheumatoid arthritis: Possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 21 Suppl 31 (2003) S154-S157
60. Quinn M.A., and Cox S. The evidence for early intervention. Rheum Dis Clin North Am. 31 (2005) 575-589
61. Cush J.J. Early rheumatoid arthritis-is there a window of opportunity. J Rheumatol Suppl. 80 (2007) 1-7
62. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 46 (2002) 328-346
63. Luqmani R., Hennell S., Estrach C., et al., the British Society for Rheumatology, British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group. British Society for Rheumatology and British health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford) 45 (2006) 1167-1169
64. March L., and Lapsley H. What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 15 (2001) 171-185
65. Korthals-de Bos I., Van Tulder M., Boers M., et al. Indirect and total costs of early rheumatoid arthritis: A randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone. J Rheumatol. 31 (2004) 1709-1716
66. Mäkinen H., Kautiainen H., Hannonen P., and Sokka T. Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. A 5-year follow-up study. J Rheumatol. 32 (2005) 796-800
67. Khanna D., Oh M., Furst D.E., et al., the Western Consortium of Practicing Rheumatologists. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum. 57 (2007) 440-447
68. van der Helm-van Mil A.H., Breedveld F.C., and Huizinga T.W. Aspects of early arthritis. Definition of disease states in early arthritis: Remission versus minimal disease activity. Arthritis Res Ther. 8 (2006) 216
69. Ranganath V.K., Khanna D., and Paulus H.E. ACR remission criteria and response criteria. Clin Exp Rheumatol. 24 Suppl 43 (2006) S-14-S-21
70. US Food and Drug Administration. Guidance for industry. Clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (RA). http://www.fda.gov/cder/gdlns/rheumcln.htm Accessed September 5, 2008
71. Bakker M.F., Jacobs J.W., Verstappen S.M., and Bijlsma J.W. Tight control in the treatment of rheumatoid arthritis: Efficacy and feasibility [published correction appears in Ann Rheum Dis. 2008;7:140]. Ann Rheum Dis. 66 Suppl 3 (2007) iii56-iii60
72. Hyrich K.L., Lunt M., Watson K.D., et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum. 56 (2007) 13-20
73. Solau-Gervais E., Laxenaire N., Cor-tet B., et al. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 45 (2006) 1121-1124
74. Moreland L.W., Alten R., Van den Bosch F., et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46 (2002) 1470-1479
75. Kremer J.M., Dougados M., Emery P., et al. Treatment of rheumatoid arthritis with the selective costimula-tion modulator abatacept: Twelvemonth results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52 (2005) 2263-2271
76. Genovese M.C., Becker J.C., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 353 (2005) 1114-1123
77. Kremer J.M., Genant H.K., Moreland L.W., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med. 144 (2006) 865-876
78. Weinblatt M., Combe B., Covucci A., et al. Safety of the selective costimu-lation modulator abatacept in rheumatoid arthritis patients receiving background biologic and non-biologic disease-modifying antirheu-matic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 54 (2006) 2807-2816
79. Moreland L.W., Schiff M.H., Baumgartner S.W., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 130 (1999) 478-486
80. Bathon J.M., Martin R.W., Fleischmann R.M., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published corrections appear in N Engl J Med. 2001;344:240 and N Engl J Med. 2001;344:76]. N Engl J Med. 343 (2000) 1586-1593
81. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50 (2004) 1400-1411
82. Furst D.E., Schiff M.H., Fleischmann R.M., et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheu-matic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 30 (2003) 2563-2571
83. Smolen J.S., Van Der Heijde D.M., Clair E.W., et al., the ASPIRE Study Group. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset. Arthritis Rheum. 54 (2006) 702-710
84. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al., the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite metho-trexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54 (2006) 1390-1400
85. Cohen S.B., Emery P., Greenwald M.W., et al., the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, doubleblind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54 (2006) 2793-2806
86. Wells G., Li T., Maxwell L., Maclean R., and Tugwell P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis. 67 (2008) 260-265
87. Genovese M.C., Schiff M., Luggen M., et al. Efficacy and safety of the selective co-stimulation modulator abata-cept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 67 (2008) 547-554
88. Michaud K., Bombardier C., and Emery P. Quality of life in patients with rheumatoid arthritis: Does abatacept make a difference. Clin Exp Rheumatol. 25 Suppl 46 (2007) S35-S45
89. Möttönen T., Hannonen P., Leirisalo-Repo M., et al., the FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. Lancet. 353 (1999) 1568-1573
90. Puolakka K., Kautiainen H., Möttönen T., et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: A five-year randomized follow-up trial. Arthritis Rheum. 50 (2004) 55-62
91. Puolakka K., Kautiainen H., Möttönen T., et al., the FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: Five-year experience from the FIN-RACo trial. Arthritis Rheum. 52 (2005) 36-41
92. Grigor C., Capell H., Stirling A., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A singleblind randomised controlled trial. Lancet 364 (2004) 263-269
93. Allaart C.F., Breedveld F.C., and Dijkmans B.A. Treatment of recent-onset rheumatoid arthritis: Lessons from the BeSt study. J Rheumatol Suppl. 80 (2007) 25-33